BGI-Shenzhen Extends Tender Offer for Complete Genomics, Inc.
News Jan 07, 2013
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on December 28, 2012, approximately 17,822,265 shares, or approximately 50%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins LLP.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.